Mycoderm Topical Powder / Dusting
Butyl hydroxybenzoate, Salicylic acid, Sodium propionate
"10mg, 40mg, 2mg/g"
EGO PHARMACEUTICALS PTY. LTD.
| Pack size | 75g Dispenser Container |
|---|---|
| Dispensing mode | POM |
| Source | AUSTRALIA |
| Agent | AMREET TRADING CO. LTD. |
| Retail Price | AED |
Indications
Mycoderm Topical Powder / Dusting is used for:
SALICYLIC ACID
Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts
Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Butyl hydroxybenzoate, Salicylic acid, Sodium propionate :
Mechanism of Action
SALICYLIC ACID
Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (cox-1 and cox-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (udpg) competitively with nicotinamide adenosine dinucleotide (nad) and noncompetitively with udpg. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (udpga) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis
Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (cox-1 and cox-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (udpg) competitively with nicotinamide adenosine dinucleotide (nad) and noncompetitively with udpg. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (udpga) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis
Note
Mycoderm "10mg, 40mg, 2mg/g" Topical Powder / Dusting manufactured by EGO PHARMACEUTICALS PTY. LTD.. Its generic name is Butyl hydroxybenzoate, Salicylic acid, Sodium propionate. Mycoderm is availble in United Arab Emirates.
Farmaco UAE drug index information on Mycoderm Topical Powder / Dusting is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.